Manufacturer of Controlled Substances; Notice of Application; Rhodes Technologies, 34072-34073 [2012-13919]
Download as PDF
<![CDATA[
34072
Federal Register / Vol. 77, No. 111 / Friday, June 8, 2012 / Notices
Drug
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
Opium, raw (9600) .......................................................................................................................................................................................
Opium extracts (9610) .................................................................................................................................................................................
Opium fluid extract (9620) ...........................................................................................................................................................................
Opium tincture (9630) ..................................................................................................................................................................................
Opium poppy/Poppy Straw (9650) ..............................................................................................................................................................
Poppy Straw Concentrate (9670) ................................................................................................................................................................
Opium, granulated (9640) ...........................................................................................................................................................................
Oxycodone (9143) .......................................................................................................................................................................................
Oxymorphone (9652) ...................................................................................................................................................................................
Pentobarbital (2270) ....................................................................................................................................................................................
Phenazocine (9715) ....................................................................................................................................................................................
Phencyclidine (7471) ...................................................................................................................................................................................
Phenmetrazine (1631) .................................................................................................................................................................................
Phenylacetone (8501) .................................................................................................................................................................................
Piminodine (9730) .......................................................................................................................................................................................
Powdered opium (9639) ..............................................................................................................................................................................
Racemethorphan (9732) ..............................................................................................................................................................................
Racemorphan (9733) ...................................................................................................................................................................................
Remifentanil (9739) .....................................................................................................................................................................................
Secobarbital (2315) .....................................................................................................................................................................................
Sufentanil (9740) .........................................................................................................................................................................................
Tapentadol (9780) .......................................................................................................................................................................................
Thebaine (9333) ..........................................................................................................................................................................................
The company plans to import small
quantities of the listed controlled
substances for the National Institute on
Drug Abuse (NIDA) for research
activities.
Comments and requests for hearings
on applications to import narcotic raw
material are not appropriate. 72 FR 3417
(2007).
In regard to the non-narcotic raw
material, any bulk manufacturer who is
presently, or is applying to be,
registered with DEA to manufacture
such basic classes of controlled
substances listed in schedule I or II,
which fall under the authority of section
1002(a)(2)(B) of the Act (21 U.S.C.
952(a)(2)(B)) may, in the circumstances
set forth in 21 U.S.C. 958(i), file
comments or objections to the issuance
of the proposed registration and may, at
the same time, file a written request for
a hearing on such application pursuant
to 21 CFR 1301.43 and in such form as
prescribed by 21 CFR 1316.47.
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than July 9, 2012.
This procedure is to be conducted
simultaneously with, and independent
of, the procedures described in 21 CFR
1301.34(b), (c), (d), (e), and (f). As noted
in a previous notice published in the
Federal Register on September 23, 1975,
40 FR 43745–46, all applicants for
registration to import a basic class of
any controlled substances in schedule I
or II are, and will continue to be,
VerDate Mar<15>2010
16:23 Jun 07, 2012
Jkt 226001
required to demonstrate to the Deputy
Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration, that the requirements
for such registration pursuant to 21
U.S.C. 958(a); 21 U.S.C. 823(a); and 21
CFR 1301.34(b), (c), (d), (e), and (f) are
satisfied.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–13920 Filed 6–7–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Importer of Controlled Substances;
Notice of Registration; Meda
Pharmaceuticals, Inc.
By Notice dated April 2, 2012, and
published in the Federal Register on
April 12, 2012, 77 FR 21998, Meda
Pharmaceuticals, Inc., 705 Eldorado
Street, Decatur, Illinois 62523, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as an importer of Nabilone
(7379), a basic class of controlled
substance listed in schedule II.
The company plans to import the
listed controlled substance for
distribution to its customers.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a) and 952(a),
and determined that the registration of
Meda Pharmaceuticals Inc. to import the
basic class of controlled substance is
PO 00000
Frm 00070
Fmt 4703
Sfmt 4703
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
II
consistent with the public interest, and
with United States obligations under
international treaties, conventions, or
protocols in effect on May 1, 1971. DEA
has investigated Meda Pharmaceuticals
Inc. to ensure that the company’s
registration is consistent with the public
interest. The investigation has included
inspection and testing of the company’s
physical security systems, verification
of the company’s compliance with state
and local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C. 952(a)
and 958(a), and in accordance with 21
CFR 1301.34, the above named company
is granted registration as an importer of
the basic class of controlled substance
listed.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–13916 Filed 6–7–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
Rhodes Technologies
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on May 1, 2012,
Rhodes Technologies, 498 Washington
Street, Coventry, Rhode Island 02816,
made application to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
E:\FR\FM\08JNN1.SGM
08JNN1
Federal Register / Vol. 77, No. 111 / Friday, June 8, 2012 / Notices
Morphine (9300), a basic class of
controlled substance listed in schedule
II.
The company plans to manufacture
the listed controlled substance in bulk
for conversion and sale to dosage form
manufacturers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 7, 2012.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control. Drug Enforcement
Administration.
[FR Doc. 2012–13919 Filed 6–7–12; 8:45 am]
BILLING CODE 4410–09–P
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Application;
S&B Pharma, Inc.
Pursuant to § 1301.33(a), Title 21 of
the Code of Federal Regulations (CFR),
this is notice that on April 4, 2012, S&B
Pharma Inc., 405 South Motor Avenue,
Azusa, California 91702–3232, made
application to the Drug Enforcement
Administration (DEA) to be registered as
a bulk manufacturer of the following
basic classes of controlled substances:
Drug
Schedule
mstockstill on DSK4VPTVN1PROD with NOTICES
Gamma
Hydroxybutyric
Acid
(2010).
Tetrahydrocannabinols (7370) .....
Methamphetamine (1105) ............
Pentobarbital (2270) .....................
Nabilone (7379) ............................
I
I
II
II
II
The company plans to manufacture
bulk controlled substances for use in
product development and for
distribution to its customers.
Any other such applicant, and any
person who is presently registered with
DEA to manufacture such substances,
may file comments or objections to the
issuance of the proposed registration
pursuant to 21 CFR 1301.33(a).
Any such written comments or
objections should be addressed, in
quintuplicate, to the Drug Enforcement
VerDate Mar<15>2010
16:23 Jun 07, 2012
Jkt 226001
Administration, Office of Diversion
Control, Federal Register Representative
(ODL), 8701 Morrissette Drive,
Springfield, Virginia 22152; and must be
filed no later than August 7, 2012.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
[FR Doc. 2012–13918 Filed 6–7–12; 8:45 am]
BILLING CODE 4410–09–P
34073
OFFICE OF MANAGEMENT AND
BUDGET
Office of Federal Procurement Policy
Value Engineering
Office of Federal Procurement
Policy, Office of Management and
Budget.
AGENCY:
Proposed revision to Office of
Management and Budget Circular No.
A–131, ‘‘Value Engineering’’.
ACTION:
The Office of Federal
Procurement Policy (OFPP) in the Office
of Management and Budget (OMB) is
proposing to revise OMB Circular A–
131, Value Engineering, to update and
reinforce policies associated with the
consideration and use of Value
Engineering (VE). VE is an effective
technique for cutting waste and
inefficiency—helping Federal agencies
save billions of dollars in program and
acquisition costs, improve performance,
enhance quality, and foster the use of
innovation. The proposed revisions are
designed to ensure that the Federal
Government has the capabilities and
tools to consider and apply VE
techniques to the maximum extent
appropriate.
SUMMARY:
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled
Substances; Notice of Registration;
Pharmagra Labs, Inc.
By Notice dated January 30, 2012, and
published in the Federal Register on
February 6, 2012, 77 FR 5846,
Pharmagra Labs Inc., 158 McLean Road,
Brevard, North Carolina 28712, made
application by renewal to the Drug
Enforcement Administration (DEA) to
be registered as a bulk manufacturer of
Pentobarbital (2270), a basic class of
controlled substance in schedule II.
The company plans to manufacture
the listed substance for analytical
research and clinical trials.
No comments or objections have been
received. DEA has considered the
factors in 21 U.S.C. 823(a), and
determined that the registration of
Pharmagra Labs, Inc. to manufacture the
listed basic class of controlled substance
is consistent with the public interest at
this time. DEA has investigated
Pharmagra Labs, Inc. to ensure that the
company’s registration is consistent
with the public interest. The
investigation has included inspection
and testing of the company’s physical
security systems, verification of the
company’s compliance with state and
local laws, and a review of the
company’s background and history.
Therefore, pursuant to 21 U.S.C.
823(a), and in accordance with 21 CFR
1301.33, the above named company is
granted registration as a bulk
manufacturer of the basic class of
controlled substance listed.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of
Diversion Control, Drug Enforcement
Administration.
Interested parties should submit
comments in writing to the address
below on or before August 7, 2012.
DATES:
Comments may be
submitted by any of the following
methods:
• Online at: https://
www.regulations.gov.
• Facsimile: 202–395–5105.
• Mail: Office of Federal Procurement
Policy, ATTN: Curtina Smith, New
Executive Office Building, Room 9013,
725 17th Street NW., Washington, DC
20503.
Instructions: Please submit comments
only and cite ‘‘Proposed Revision to
OMB Circular A–131’’ in all
correspondence. All comments received
will be posted, without change or
redaction, to www.regulations.gov, so
commenters should not include
information that they do not wish to be
posted (for example because they
consider it personal or business
confidential).
ADDRESSES:
FOR FURTHER INFORMATION CONTACT:
[FR Doc. 2012–13917 Filed 6–7–12; 8:45 am]
Curtina Smith, OFPP,
csmith@omb.eop.gov. Availability:
Copies of the proposed revision to OMB
Circular A–131 are available on OMB’s
Web site at https://www.whitehouse.gov/
omb/circulars_default/.
BILLING CODE 4410–09–P
SUPPLEMENTARY INFORMATION:
PO 00000
Frm 00071
Fmt 4703
Sfmt 4703
E:\FR\FM\08JNN1.SGM
08JNN1
]]>Agencies
[Federal Register Volume 77, Number 111 (Friday, June 8, 2012)]
[Notices]
[Pages 34072-34073]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 2012-13919]
-----------------------------------------------------------------------
DEPARTMENT OF JUSTICE
Drug Enforcement Administration
Manufacturer of Controlled Substances; Notice of Application;
Rhodes Technologies
Pursuant to Sec. 1301.33(a), Title 21 of the Code of Federal
Regulations (CFR), this is notice that on May 1, 2012, Rhodes
Technologies, 498 Washington Street, Coventry, Rhode Island 02816, made
application to the Drug Enforcement Administration (DEA) to be
registered as a bulk manufacturer of
[[Page 34073]]
Morphine (9300), a basic class of controlled substance listed in
schedule II.
The company plans to manufacture the listed controlled substance in
bulk for conversion and sale to dosage form manufacturers.
Any other such applicant, and any person who is presently
registered with DEA to manufacture such substances, may file comments
or objections to the issuance of the proposed registration pursuant to
21 CFR 1301.33(a).
Any such written comments or objections should be addressed, in
quintuplicate, to the Drug Enforcement Administration, Office of
Diversion Control, Federal Register Representative (ODL), 8701
Morrissette Drive, Springfield, Virginia 22152; and must be filed no
later than August 7, 2012.
Dated: May 31, 2012.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control. Drug
Enforcement Administration.
[FR Doc. 2012-13919 Filed 6-7-12; 8:45 am]
BILLING CODE 4410-09-P
